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Abstract We investigated whether basal insulin as first-
line treatment in recently diagnosed type 2 diabetes (T2D)
can improve glucose control, microvascular function and
preserve insulin secretion in comparison with metformin
(MET). In this open-label, randomized, prospective 36-week
study, 75 patients (44 m, 31 f, mean age 60.7 ± 9.2 year)
were allocated to treatment with either MET 1,000 mg b.i.d.
(n = 36) or insulin glargine (GLA) at bedtime (n = 39). At
baseline and study end, we performed a continuous glucose
monitoring for assessment of interstitial glucose (IG) and
measured microvascular function using Laser-Doppler
fluxmetry. GLA versus MET treatment resulted in a
more pronounced reduction in FPG (D: 3.1 ± 2.5 vs.
1.4 ± 1.5 mmol/l; p \ 0.001) and overall IG (D AUC.
671 ± 507 vs. 416 ± 537 mmol/l min; p = 0.04). Post-
prandial PG and IG differences after a standardized test meal
did not reach significance. Proinsulin/C-peptide and HOMA
B as marker of endogenous insulin secretion were signifi-
cantly more improved by GLA. Microvascular blood flow
improved only in MET-treated patients. Early basal insulin
treatment with GLA in T2D patients provided a better con-
trol of FPG, overall IG load and biomarker of beta-cell
function compared to the standard treatment with MET.
MET treatment resulted in an improvement of microvascular
function. Studies of longer duration are needed to evaluate
the durability of glucose control and b cell protection with
early GLA treatment.
Keywords Insulin glargine  Continuous glucose
monitoring  CGM  Laser-doppler  Beta-cell
Introduction
Type 2 diabetes mellitus is characterized by an impaired
insulin secretion in response to glucose stimulation [1].
With ongoing disease duration, most patients show a
progressive reduction in b-cell mass and deterioration in
beta-cell function [2, 3]. Current treatment guidelines
recommend the introduction of metformin at diagnosis in
combination with diet and exercise as first-line therapy for
type 2 diabetes [4]. However, metformin does not prevent
progression of type 2 diabetes over long term as consistently
shown by the UK prospective diabetes study (UK-PDS)
or a diabetes outcome progression trial (ADOPT) [5, 6].
Chronic hyperglycemia has harmful effects on glucose-
induced insulin secretion and might accelerate apoptosis of
b-cells [7]. Furthermore, chronic hyperglycemia can dete-
riorate endothelial function [8]. This glucotoxic effect
became apparent if blood glucose concentration exceeds
6.4 mmol/l and is primarily associated with a deterioration
of pulsatile insulin secretion and acute insulin response to a
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glucose load [7]. Insulin therapy according to guidelines is
usually introduced late in the course of the disease [4].
However, recently published trials have demonstrated a
sustained improvement of endogenous insulin secretion by
early short-term exogenous insulin supplementation
[9, 10]. In addition, an outcome trial with basal insulin
glargine compared to standard care demonstrated a sig-
nificant reduction in incident type 2 diabetes by 28 % in
insulin-treated participants without diabetes at baseline
[11]. These results suggest that strict glucose control with
early insulin treatment may protect b-cells from harmful
effects of glucotoxicity. Long acting insulin analogs pro-
vide good glycemic control together with a low risk of
hypoglycemia [12]. The initiation of basal insulin treat-
ment early in the course of the disease may help to mini-
mize the required insulin dosage and therefore adverse
effects on body weight [13]. In contrast to metformin
which cannot be used in several patients, for example, with
advanced renal impairment, basal insulin may be used
regardless of concomitant diseases [14].
The aim of our study was to evaluate the effects of basal
insulin glargine in patients with drug naı¨ve type 2 diabetes
(\5 years) on quality of glucose control as well as on beta-
cell function and microvascular blood flow in comparison
with metformin.
Materials and methods
Study protocol and patients
Ninety-six patients were included into this multicenter,
open-label, prospective study to receive either metformin at
a target dose of 1,000 mg b.i.d. or insulin glargine once-daily
at bedtime. Insulin dose was titrated stepwise to a target
fasting glucose of B5.6 mmol/l according to a standardized
titration schedule [15]. All insulin-treated patients were
instructed to assess their fasting blood glucose daily using the
FreeStyle Lite (Abbott, Wiesbaden, Germany) and to
adjust their insulin dose to target. In addition, all patients
were asked to self-assess blood glucose if they experienced
clinical symptoms of hypoglycemia.
Main inclusion criteria for the study were a drug naı¨ve
type 2 diabetes mellitus with\5 years after diagnosis and a
HbA1c between 6.5 and 8 %. Main exclusion criteria were
renal dysfunction with a calculated glomerular filtration
rate below 60 ml/min, acute or chronic diseases which
could lead to tissue hypoxia, the use of intravascular con-
trast agents throughout the study, increase in serum trans-
aminases more than 2.5-fold of the upper limit of the
normal range, or systemic corticosteroid treatment. At
baseline and after 36 weeks of treatment, all patients
received a 72 h continuous interstitial glucose monitoring
(CGM) with a standardized test meal at day 2 and a test of
microvascular blood flow. All patients got a reinforcement
of dietary counseling at study entry and throughout the
study. Dietary records of the patients were analyzed by
specialized staff at each visit date to prevent weight gain.
The study protocol was approved by the ethics committee
of the Saxony chamber of physicians. All patients gave
written informed consent before inclusion.
Continuous glucose monitoring
We used the Medtronic System GoldTM Monitor with
MiniMed glucose subcutaneous sensors (Medtronic Mini-
Med, Northridge, CA). The system is approved for a con-
tinuous measurement of interstitial glucose (IG) every
5 min over 72 h within the subcutaneous fat tissue. Anal-
ysis was limited to the data obtained from the intermediate
48 h of recording to avoid bias due to insertion and
removal of the CGM. On the morning of the second day of
CGM, a standardized test meal was consumed by the
patients at the study site. The test meal consisted of 95 g
whole-grain bread, 20 g margarine, 25 g jam, 25 g cheese,
200 ml orange juice, and 200 ml milk mix drink which
corresponds to 50 % carbohydrates, 35 % fat, and 15 %
proteins with a total energy content of 511 kcal.
For the assessment of glycemic variability, we calcu-
lated the overall area under the IG curve (AUC) and the
incremental area under the glucose curve of the test meal
(incAUC) and assessed the mean IG, standard deviation
(SD) of IG, and mean average glucose excursions
(MAGE). MAGE was calculated as the arithmetic mean of
the differences between consecutive peaks and nadirs,
provided that the differences are greater than one SD of the
mean glucose value.
Laser-Doppler measurement of microcirculation
Microvascular skin blood flow has been assessed using
Laser-Doppler fluxmetry (O2C, LEA Medizintechnik,
Giessen, Germany) as described [16]. The skin probe was
placed at the dorsal thenar site of the left hand in between
the phalanx of the thumb and metatarsal bone of the 2nd
digit. Measurements were performed at 2 mm depth with a
continuously emitted laser light (wavelength 830 nm). The
movement of erythrocytes within the sample volume cau-
ses a Doppler shift effect of the laser light which allows for
the calculation of the flow velocity and consequently the
relative blood flow, which is expressed in arbitrary units
(U). We measured the pre-ischemic blood flow (pBF) and
the maximal post-ischemic blood flow (maxBF) during
reactive hyperemia after 5 min of suprasystolic ischemia of
the forearm. Average pBF was calculated over 4 min and
maxBF was recorded as peak blood flow 20–40 s after cuff
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release. The same location of the skin probe was used for
repeated measurements; patients rested at least 30 min in a
quite temperature-controlled room prior to the start of the
examination.
Biochemical analysis
HbA1c was measured chromatographically using HPLC
(TOSOH G8, Stuttgart, Germany); insulin, proinsulin, and
C-peptide were measured with EIA (TOSOH AIA 360,
Stuttgart, Germany); triglycerides were measured with the
GPO-PAP method; LDL and HDL cholesterol fractions
were measured by enzymatic tests on the Konelab 20xTi
(ThermoFisher, Dreieich, Germany).
Homeostasis model assessment was used to estimate
basal beta-cell function (HOMA B) and insulin resistance
(HOMA IR). HOMA B was calculated as 20 9 fasting
insulin/(fasting plasma glucose - 3.5) and HOMA IR as
fasting plasma glucose 9 fasting insulin/22.5.
Statistical analysis
All continuous parameters are expressed as mean ± SD if
not indicated otherwise. Not normally distributed variables
were log-transformed. Student’s t test for comparisons
between treatment groups and paired t test for comparisons
within a treatment group (i.e., first vs. last visit) were
applied. The primary objective was the change of IG–
AUC, and therefore, we performed a per protocol analysis.
The calculated power for the primary objective was 78 %.
Not normally distributed variables were analyzed using
Mann–Whitney U test. Categorical variables were com-
pared by chi square test. Differences of baseline variables
between study groups were considered using an analysis of
covariates (ANCOVA) for the evaluation of treatment
effects. A p value \ 0.05 indicated statistical significant
differences. All statistical analyses were performed using
SPSS 19.0 software.
Results
Seventy-five out of 97 randomized patients finished the
study per protocol. The dropout rate was identical between
metformin (n = 5)- and glargine (n = 6)-treated patients.
In 11 patients, CGM at the end of study could not be
analyzed due to recording problems.
Baseline clinical parameters were well balanced
between treatment groups (Table 1). Interstitial glucose
monitoring demonstrated a more pronounced reduction in
mean IG and AUC with insulin glargine, whereas the
reduction in the incremental AUC was comparable
between treatments (Table 2). However, after 36 weeks of
treatment, we found nearly identical IG curves (Fig. 1) for
insulin and metformin. Glycemic variability (expressed as
MAGE or SD) at the study end was significantly higher
with insulin glargine; however, the change from baseline
was at the same range for both indices (Table 2).
Insulin glargine treatment primarily reduced fasting
hyperglycemia with first significant difference of FPG
occurring after 8 weeks, mainly as an effect of stepwise
insulin titration, and FPG remained significantly different
between treatments until end of study (Fig. 2a). However,
the between group difference did not reach significance level
for change of HbA1c or PPG 2 h after the test meal (Table 2)
which was in agreement with the IG parameter (Fig. 1).
Proinsulin as a marker of b-cell dysfunction was significantly
reduced by both treatments. Of notice, this reduction was
more pronounced in the glargine-treated patients in the
fasting and postprandial state (Table 2). Due to insulin
supplementation, fasting endogenous insulin secretion
(assessed by C-peptide concentration) was decreased in the
glargine group, whereas postprandial endogenous insulin
secretion was preserved (Table 2). Consequently, the
HOMA B (Table 2) as well as proinsulin/C-peptide ratio
after the test meal (Fig. 3) as marker of endogenous insulin
secretion and therefore beta-cell function were significantly
more improved by insulin glargine.
Microvascular blood flow after 36 weeks of treatment
was identical with insulin and metformin. However, the
post-ischemic microvascular response improved in met-
formin-treated patients but not in insulin-treated patients
(Table 2).
Despite intensive dietary counseling, glargine-treated
patients gained weight (Fig. 2b) associated with a signifi-
cant increase in waist circumference of 1.1 ± 3.7 cm
versus a decrease of 1.9 ± 4.1 cm in the metformin group
(p \ 0.001).
The mean insulin dose at study end was 25.9 ± 13.2 U
(0.3 ± 0.1 U/kg body weight).
Hypoglycemic episodes during BG self-monitoring—
defined as any BG value \3.1 mmol/l or symptoms of






Sex female n (%) 18 (50) 13 (33.3) 0.220
Age (year) 62.03 ± 9.4 60 ± 9.3 0.348
Diabetes duration
(year)
2.6 ± 1.6 2.8 ± 1.4 0.602
BMI (kg/m2) 29.9 ± 5.3 29.2 ± 4.6 0.537
Weight (kg) 87.6 ± 17.9 87.6 ± 15.1 0.965
Waist (cm) 102.5 ± 14.5 103.7 ± 11.1 0.678
Systolic BP (Torr) 141.5 ± 14.8 141 ± 15.7 0.896
Diastolic BP (Torr) 81.2 ± 10.4 85.3 ± 9.8 0.133
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Table 2 Glycemic parameter assessed by continuous glucose monitoring, biomarker of beta-cell function and biochemical parameter
Metformin (n = 36) Insulin glargine (n = 39) p
Parameter of glucose control
FPG baseline (mmol/l) 8.7 ± 1.6 9.2 ± 2.1 0.297
FPG week 36 (mmol/l) 7.2 ± 1 6.1 ± 1.1 0.001
FPG change (mmol/l) -1.4 ± 1.5 -3.1 ± 2.5 0.001
PPG 1200 baseline (mmol/l) 10.3 ± 2.8 11.1 ± 4.5 0.415
PPG 1200 week 36 (mmol/l) 8.4 ± 2.1 8.3 ± 2.5 0.832
PPG 1200 change (mmol/l) -1.6 ± 2.5 -2.8 ± 3.2 0.106
HbA1c baseline (%) 6.9 ± 0.4 7.2 ± 0.7 0.045
HbA1c week 36 (%) 6.31 ± 0.4 6.36 ± 0.4 0.478
HbA1c change (%) -0.6 ± 0.41 -0.8 ± 0.69 0.087
Interstitial glucose measurements
AUC baseline (mmol l-1 min) 2387.0 ± 500.3 2671.5 ± 598.5 0.029
AUC week 36 (mmol l-1 min) 1971.8 ± 337.8 2000.3 ± 313.1 0.774
AUC change (mmol l-1 min) -416.1 ± 537.6 -671.2 ± 507.9 0.039
incAUC baseline (mmol l-1 min) 55.4 ± 30.2 73.9 ± 39.9 0.027
incAUC week 36 (mmol l-1 min) 49.6 ± 25.0 68.3 ± 24.6 0.002
incAUC change (mmol l-1 min) -5.8 ± 31.8 -5.7 ± 40.4 0.989
Mean IG baseline (mmol/l) 8.3 ± 1.7 9.4 ± 2.1 0.015
Mean IG week 36 (mmol/l) 6.9 ± 1.2 7.0 ± 1.0 0.573
Mean IG change (mmol/l) -1.4 ± 1.8 -2.4 ± 1.7 0.022
MAGE baseline 3.3 ± 0.9 4.0 ± 1.1 0.001
MAGE week 36 2.9 ± 1.1 3.7 ± 1.0 0.001
MAGE change -0.4 ± 1.7 -0.3 ± 1.3 0.676
SD baseline 1.6 ± 0.8 1.8 ± 0.6 0.121
SD week 36 1.3 ± 0.5 1.7 ± 0.5 0.001
SD change -0.2 ± 0.7 -0.07 ± 0.7 0.45
Parameter of beta-cell function
Proinsulin 00 baseline (pmol/l) 8.6 ± 6.2 13.0 ± 13.5 0.023
Proinsulin 00 wk 36 (pmol/l) 5.8 ± 4.6 5.4 ± 5.0 0.35
Proinsulin 00 change (pmol/l) -3 ± 4.1 -7.6 ± 10.8 0.001
Proinsulin 1200 baseline (pmol/l) 26.8 ± 16.0 37.8 ± 32.2 0.069
Proinsulin 1200 week 36 (pmol/l) 20.4 ± 19.9 26.8 ± 29 0.259
Proinsulin 1200 change (pmol/l) -6.6 ± 14.3 -11.1 ± 26.8 0.019
C-peptide 00 baseline (nmol/l) 1.0 ± 0.5 0.9 ± 0.4 0.453
C-peptide 00 week 36 (nmol/l) 0.9 ± 0.4 0.5 ± 0.3 0.001
C-peptide 00 change (nmol/l) -0.1 ± 0.3 -0.4 ± 0.4 0.001
C-peptide 1200 baseline (nmol/l) 2.7 ± 1.1 2.4 ± 1.0 0.274
C-peptide 1200 week 36 (nmol/l) 2.6 ± 1.3 2.2 ± 1.0 0.274
C-peptide 1200 change (nmol/l) 0 ± 0.7 -0.2 ± 0.8 0.348
Insulin 00 baseline (pmol/l) 90.6 ± 51.2 85.1 ± 48.6 0.733
Insulin 00 week 36 (pmol/l) 71.6 ± 43.0 104.4 ± 62.9 0.01
Insulin 00 change (pmol/l) -19.2 ± 26.0 19.2 ± 47.9 0.001
Insulin 1200 baseline (pmol/l) 445.2 ± 303 401.8 ± 296.2 0.487
Insulin 1200 week 36 (pmol/l) 364.6 ± 285 448.8 ± 371.9 0.416
Insulin 1200 change (pmol/l) -79.9 ± 216.9 46.6 ± 275.6 0.06
Insulin/proinsulin 1200 baseline 22.2 ± 29.1 12.5 ± 7.5 0.063
Insulin/proinsulin 1200 week 36 24.7 ± 27.1 20.7 ± 11.8 0.410
Insulin/proinsulin 1200 change 3.0 ± 8.4 8.2 ± 9.4 0.015
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hypoglycemia—occurred rarely and were more often
reported in insulin-treated patients (Table 2). The mean
duration of IG episodes \3.9 mmol/l during CGM was
similar between treatment groups (Table 2). There was no
severe hypoglycemia and only one symptomatic hypogly-
cemia reported in the glargine group during the study. Main
adverse events in metformin-treated patients were gastroin-
testinal complaints, that is, discomfort, flatulence, and diar-
rhea (Table 2). However, despite such undesired side effects
of metformin, most of the patients which completed the study
received the target dose of 2,000 mg metformin per day
(mean dose at end of study 1,883 ± 357 mg).
Discussion
For the first time, our study investigated the effects of basal
insulin versus metformin on glycemic control, beta-cell
function, and microvascular blood flow when used as first-
line treatment of type 2 diabetes. In contrast to other
studies of rather short duration with various regimes of
insulin application [9, 10, 17, 18], the present prospective
randomized trial allowed us to compare the effects of dif-
ferent treatments on beta-cell function and blood flow at
the same level of HbA1c and hence chronic hyperglycemia.
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Fig. 1 Mean interstitial glucose
values of the second day
(including a standardized
breakfast) after 36 weeks of
treatment with insulin glargine
or metformin
Table 2 continued
Metformin (n = 36) Insulin glargine (n = 39) p
HOMA B baseline 49.4 ± 34.5 48.2 ± 36.7 0.893
HOMA B week 36 56.3 ± 34.5 128 ± 99 0.001
HOMA B change 4.4 ± 19.5 77.2 ± 97.8 0.001
HOMA IR baseline 5.0 ± 3.7 4.9 ± 3.8 0.893
HOMA IR week 36 3.2 ± 2.0 4.0 ± 2.4 0.116
HOMA IR change -1.8 ± 1.8 -1.1 ± 3.0 0.239
Blood flow measurements
Pre-ischemic BF baseline (U) 23.3 ± 13.4 25.8 ± 14.7 0.350
Pre-ischemic BF week 36 (U) 25.2 ± 13.4 26.6 ± 14.7 0.766
MaxBF baseline (U) 81.9 ± 48 99.0 ± 29.1 0.091
MaxBF week 36 (U) 90.7 ± 43 89.1 ± 32.4 0.697
MaxBF change (U) 8.8 ± 31.5 -9.9 ± 39.6 0.042
Safety parameter
Duration glucose \3.9 baseline (min) 1.5 ± 9.2 3.0 ± 13.1 0.592
Duration glucose \3.9 week 36 (min) 11.2 ± 41.4 13.6 ± 46.5 0.468
Self assessed BG \3.1 mmol/l (n) 4 14 0.045
Gastrointestinal complaints (n) 10 0 0.001
AUC area under the interstitial glucose curve, incAUC incremental area under the interstitial glucose curve of the test meal, Mean IG mean
interstitial glucose values, SD standard deviation of interstitial glucose, MAGE mean average glucose excursions, proinsulin (pmol/l); C-peptide
(nmol/l); insulin (pmol/l), 00 start of the test meal, 1200 2 h after the test meal; change displayed difference between week 36 and baseline, FPG
fasting plasma glucose, PPG postprandial plasma glucose, BF blood flow, BG blood glucose
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acceptable HbA1c (\8.5 %) and thus presumably enough
b-cell mass for improvement of beta-cell function if
harmful effects of glucotoxicity can be reduced by near to
normal glucose control.
As expected, we found a significantly improved control
of overall interstitial glucose and FPG in both groups but
insulin glargine treatment resulted in significantly lower
FPG compared to metformin (Fig. 2a). We also found a
more pronounced improvement of basal and postprandial
beta-cell function expressed by the basal ratio of HOMA
B/HOMA IR (Fig. 3a) and postprandial proinsulin/C-pep-
tide ratio (Fig. 3b) in insulin-treated patients. However,
despite these more pronounced effects on FPG and beta-
cell function, we did not find a significant difference of
postprandial or overall interstitial glucose load and HbA1c
with insulin glargine compared to metformin at study end
(Fig. 1). These results are in agreement with data from the
recently published Outcome Reduction with an Initial
Glargine Intervention (ORIGIN) that demonstrated a more
pronounced effect of insulin glargine on FPG than on
HbA1c compared to standard care [11]. One possible
explanation for similar effects of insulin glargine on quality
of glucose control compared to metformin in the present
study could be the differences in body weight gain, visceral
obesity, and insulin resistance after 36 weeks of treatment.
The improvement of endogenous insulin secretion after
insulin treatment did not completely outweigh insulin
resistance as demonstrated by insulin and plasma glucose
values 2 h after the test meal.
A previous study by Alvarsson et al. [19] investigated
the effects of insulin treatment on stimulated C-peptide
secretion in comparison with sulfonylurea over a 2-year
period. The authors reported an increase in stimulated
C-peptide response after insulin treatment and a decreased
response after sulfonylurea. This was accompanied by a
significantly lower HbA1c value after 2 years in insulin-
treated patients. However, these patients had a comparable
weight gain throughout the study and similar degree of
insulin resistance [19].
It might be possible that the improvement of beta-cell
function due to insulin treatment will significantly affect
progression of type 2 diabetes as demonstrated by Weng
and colleagues [10]. The concept of b-cell recovery due to
basal insulin supplementation has been developed several
years ago [20]. Intermittent inhibition of endogenous
insulin secretion by somatostatin has been demonstrated to
increase the subsequent glucose-induced insulin secretion
[21]. A reduction in chronic hyperglycemia by exogenous
insulin supplementation might be equally effective as
demonstrated in recent trials [10, 18]. The latter effect can















































Fig. 2 Time course of fasting plasma glucose concentration (a) and































baseline week 36             baseline             week 36
Fig. 3 Fasting (0 min) and postprandial (120 min) beta-cell function
assessed by proinsulin/C-peptide at baseline and study end (week 36),
#p \ 0.05 vs. baseline value. Data are expressed as mean ± SEM
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be explained by a suppression of hyperglycemia-induced
reactive oxygen species [22, 23] or anti-apoptotic actions
of insulin itself [24].
We found a reduction in the post-ischemic microvascular
response in insulin-treated patients compared to baseline,
whereas metformin increased the post-ischemic microvas-
cular response and hence endothelial function (Table 2).
Previous studies demonstrated an adversative vascular
action of insulin in healthy individuals [25]: Insulin mod-
ulates endothelium-dependent vascular effects through two
distinct intracellular pathways. While the physiological
signaling of insulin in insulin-sensitive subjects is mediated
through the phosphatidylinositol-3-kinase signaling path-
way resulting in the release of nitric oxide (NO) and
vasodilation, pathological signaling through the mitogen-
activated-protein-kinase signaling pathway in insulin-
resistant subjects stimulates endothelin 1 release with sub-
sequent vasoconstriction [26]. In addition, insulin was
shown to stimulate sympathetic nerve outflow which might
also counter the vasodilatory effects of NO-mediated
vasodilation. Therefore, the resulting vascular action of
insulin depends on the vascular bed and the degree of
insulin resistance, for example, insulin eventually mediates
vasodilatation of the muscular vasculature in healthy indi-
viduals [25]. Baseline skin blood flow is mainly regulated
by sympathetic innervations and only to a lesser extent by
vascular endothelium. However; post-ischemic skin blood
flow is mediated by endothelium-dependent vasodilators
especially prostaglandins [27]. It is still under debate
whether skin blood flow is a reliable measure for general
endothelial function and a surrogate parameter of cardio-
vascular endpoints. However, there are several studies
which demonstrate a significant correlation between skin
blood flow and other techniques for assessment of endo-
thelial function [28], and there are interventional studies
which demonstrate an improvement of skin blood flow after
reduction in cardiovascular risk factors [16, 27]. Metformin
treatment resulted in a significant reduction in body weight
and an improvement of insulin sensitivity (Table 2),
whereas insulin increased body weight and improved
insulin resistance to a smaller extend than metformin. Since
insulin resistance can deteriorate endothelium-dependent
vasodilatation [29], it is conceivable that hyperinsulinemia
in combination with a nearly unchanged insulin resistance
in insulin glargine-treated patients increased the sympa-
thetic nerve outflow without a compensatory activation of
endothelium-dependent vasodilators. This finding is in
agreement with previous studies which described an
impaired insulin action on endothelium-dependent vasodi-
lation in type 2 diabetic patients [30]. There are conflicting
results about direct vascular effects of metformin treat-
ment itself; however, several studies demonstrated an
improvement of endothelial function [31, 32]. Furthermore,
insulin-treated patients in the present study had significantly
higher fluctuations of interstitial glucose—expressed as
MAGE and SD (Table 2). Glucose fluctuations itself may
contribute to the generation of oxidative stress and conse-
quently to endothelial dysfunction [33–35].
Risk of hypoglycemia was not significantly increased
with insulin despite HbA1c \6.5 % equal to metformin.
Several trials using insulin even in the prediabetic state
reported no relevant safety concerns about hypoglycemia
and only moderately increased body weight [11, 17, 36,
37]. Our study confirmed the low risk of hypoglycemia of
insulin glargine treatment by CGM recordings. The higher
rate of self-monitored asymptomatic hypoglycemic events
(8 vs. 2) might be biased due to the higher rate of glucose
self-monitoring itself in the insulin glargine-treated
patients.
A limitation of our study was the rather small sample
size and the higher than expected range of interstitial
glucose measurements and biochemical parameter. There-
fore, we cannot exclude whether the lack of a statistical
significant difference in some results was due to beta
errors. A further limitation may be the higher than aimed
FPG value in insulin-treated patients despite a differenti-
ated titration regimen. Main reason for this finding was the
day to day variation of self-monitored glucose values. In
fact, nearly all patients achieved the target value of
5.6 mmol/l of blood glucose after a median of 8 week of
treatment during the study. However, we observed day by
day fluctuations of fasting glucose by 1.5 mmol/l, which
did not allow a further up-titration of insulin dose. A FPG
at the target value might have resulted in even lower glu-
cotoxicity and better postprandial glucose values as sug-
gested by our previous study [36]. Furthermore, we did not
found a significant correlation between FPG and incre-
mental AUC and no significantly different PPG values
between insulin-treated patients who reached the target PG
of 5.6 mmol/l at week 36 (n = 15) and metformin-treated
patients (data not shown). On the other hand, as demon-
strated in Fig. 2, insulin-treated patients had significantly
lower fasting plasma glucose than metformin-treated
patients throughout the whole study period.
Do our results imply to initiate basal insulin treatment as
first-line therapy of type 2 diabetes instead of metformin?
The answer is no with regard to glycemic control and
endothelial function since we reach the same level of
postprandial or chronic hyperglycemia with both medica-
tions, and we have no improvement of microvascular
endothelial function with insulin. The answer may possible
yes with regard to beta-cell function since we know from a
recently large randomized trial that insulin treatment might
reduce the progression of type 2 diabetes [11].
Acta Diabetol (2013) 50:587–595 593
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